From the Guidelines
Vabysmo (faricimab) is typically taken every 4-8 weeks during the first 12 months of treatment, with fewer injections needed in subsequent years to maintain remission from center-involved diabetic macular edema.
Treatment Frequency
- The frequency of Vabysmo (faricimab) administration is similar to other anti-VEGF agents, such as ranibizumab and aflibercept, which are commonly used to treat center-involved diabetic macular edema 1.
- Most individuals require administration of intravitreal therapy with anti-VEGF agents every 4–8 weeks during the first 12 months of treatment, with fewer injections needed in subsequent years to maintain remission from center-involved diabetic macular edema 1.
- The treatment frequency may vary depending on the individual's response to therapy and the severity of their diabetic macular edema.
Anti-VEGF Agents
- Vabysmo (faricimab) is one of five anti-VEGF agents currently used to treat eyes with center-involved diabetic macular edema, along with bevacizumab, ranibizumab, aflibercept, and brolucizumab 1, 2.
- A comparative effectiveness study demonstrated that aflibercept provides vision outcomes superior to those of bevacizumab when eyes have moderate visual impairment from diabetic macular edema 1.
From the FDA Drug Label
2.2 Neovascular (wet) Age-Related Macular Degeneration (nAMD) The recommended dose for VABYSMO is 6 mg (0. 05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for the first 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to inform whether to give a 6 mg dose via intravitreal injection on one of the following three regimens: 1) Weeks 28 and 44; 2) Weeks 24, 36 and 48; or 3) Weeks 20, 28, 36 and 44.
2.3 Diabetic Macular Edema (DME) VABYSMO is recommended to be dosed by following one of these two dose regimens: 1) 6 mg (0. 05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days ± 7 days, monthly) for at least 4 doses
2.4 Macular Edema Following Retinal Vein Occlusion (RVO) The recommended dose for VABYSMO is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for 6 months.
The dosing frequency of Vabysmo (faricimab) varies depending on the condition being treated:
- Neovascular (wet) Age-Related Macular Degeneration (nAMD): 6 mg every 4 weeks for the first 4 doses, followed by one of three regimens: every 16 weeks, every 12 weeks, or every 8 weeks.
- Diabetic Macular Edema (DME): 6 mg every 4 weeks for at least 4 doses, with possible extension or reduction of dosing interval based on central subfield thickness and visual acuity evaluations.
- Macular Edema Following Retinal Vein Occlusion (RVO): 6 mg every 4 weeks for 6 months. 3
From the Research
Administration Frequency of Vabysmo (Faricimab)
- The administration frequency of Vabysmo (faricimab) varies depending on the condition being treated and the stage of treatment 4, 5, 6, 7, 8.
- In the BALATON and COMINO trials, patients received 6 monthly injections of faricimab 6.0 mg, followed by personalized treatment interval adjustments based on changes in central subfield thickness (CST) and best-corrected visual acuity (BCVA) 4.
- In the STAIRWAY phase 2 trial, faricimab was administered every 12 or 16 weeks, with some patients receiving dosing every 16 weeks after week 24 5.
- The AVENUE phase 2 trial evaluated different doses and regimens of faricimab, including every 4 weeks, every 8 weeks, and a combination of ranibizumab and faricimab 8.
- Real-world studies have shown that faricimab can be effective in treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) with extended dosing intervals, including every 12 or 16 weeks 6, 7.
Dosing Intervals
- The dosing intervals for faricimab can be extended based on treatment response, with some patients able to maintain treatment intervals of every 12 or 16 weeks 4, 5, 6, 7.
- Personalized treatment interval adjustments can be made based on changes in CST and BCVA, allowing for more flexible dosing regimens 4.
- The optimal dosing interval for faricimab may vary depending on the individual patient and the specific condition being treated 6, 7.